AVITA Medical (RCEL) Set to Announce Quarterly Earnings on Thursday

AVITA Medical (NASDAQ:RCEL - Get Free Report) is set to issue its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter. Investors that wish to register for the company's conference call can do so using this link.

AVITA Medical (NASDAQ:RCEL - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.01). The company had revenue of $15.20 million for the quarter, compared to analysts' expectations of $15.04 million. AVITA Medical had a negative net margin of 92.04% and a negative return on equity of 118.27%. During the same period in the prior year, the company earned ($0.41) earnings per share. On average, analysts expect AVITA Medical to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

AVITA Medical Trading Down 2.8 %

RCEL traded down $0.29 during trading on Thursday, reaching $10.10. The company had a trading volume of 55,564 shares, compared to its average volume of 185,015. The firm's 50-day simple moving average is $10.08 and its 200 day simple moving average is $9.25. The company has a debt-to-equity ratio of 1.71, a quick ratio of 4.81 and a current ratio of 5.29. The company has a market cap of $262.50 million, a price-to-earnings ratio of -5.74 and a beta of 1.54. AVITA Medical has a 12-month low of $7.51 and a 12-month high of $18.93.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald restated an "overweight" rating and set a $21.00 price target on shares of AVITA Medical in a report on Friday, August 9th.

AVITA Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.